Ghaith Abu-Zeinah

Ghaith Abu-Zeinah, MD, is an Assistant Professor of Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine (WCM) and a member of the Richard T Silver Myeloproliferative Neoplasms (MPN) Center at WCM. He specializes in the care of patients with MPNs, including polycythemia vera, essential thrombocythemia, and myelofibrosis. His clinical and translational research focuses on disease modification, molecular response, clonal evolution, and the development of personalized treatment strategies through clinical trials and real-world data. Dr. Abu-Zeinah has authored several peer-reviewed publications, serves as an investigator on national and international clinical trials, serves on a national guidelines committee, and has received honors recognizing his contributions to the field of MPNs, including the American Society of Hematology (ASH) Scholar Award and the MPN Hero Award. He is committed to advancing innovative therapies while improving outcomes and quality of life for patients with MPNs through collaborative research, education, and compassionate patient care.

Gail J.Roboz, MD is Professor of medicine and director of the clinical and translational leukemia programs at Weill Cornell Medicine and the New York Presbyterian Hospital in New York. New York, USA.

Dr. Roboz graduated summa cum laude from Yale University and Alpha Omega Alpha from the Mount Sinai School of Medicine, where she also achieved the highest academic standing in the graduating class. Dr. Roboz completed internship in Internal Medicine at the Beth Israel Hospital in Boston and residency at The New York Presbyterian Hospital. She completed fellowship in hematology and medical oncology at Weill Cornell Medical College and The New York Presbyterian Hospital.

Dr. Roboz’s research interests are in developmental therapeutics and novel clinical trial design for acute leukemias, myelodysplastic syndrome, and myeloproliferative disorders. She is the principal investigator on numerous investigator-initiated, cooperative group, and industry-sponsored clinical trials in these areas and has authored many related manuscripts and abstracts. Dr. Roboz serves on the Leukemia Core Committee for the Alliance clinical trials in oncology and is the Weill Cornell Principal Investigator for the MDS Clinical Research Consortium. She chairs the clinical committee of the European Leukemia Net (ELN) working group on minimal residual disease in acute myeloid leukemia. She also serves on the Scientific Advisory Board of the Aplastic Anemia and MDS International Foundation. Dr. Roboz has played an active role as a chair, speaker and panelist at numerous national and international conferences and is the recipient of prestigious honors and awards in the field.

Ghaith Abu-Zeinah, MD, is an Assistant Professor of Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine (WCM) and a member of the Richard T Silver Myeloproliferative Neoplasms (MPN) Center at WCM. He specializes in the care of patients with MPNs, including polycythemia vera, essential thrombocythemia, and myelofibrosis. His clinical and translational research focuses on disease modification, molecular response, clonal evolution, and the development of personalized treatment strategies through clinical trials and real-world data. Dr. Abu-Zeinah has authored several peer-reviewed publications, serves as an investigator on national and international clinical trials, serves on a national guidelines committee, and has received honors recognizing his contributions to the field of MPNs, including the American Society of Hematology (ASH) Scholar Award and the MPN Hero Award. He is committed to advancing innovative therapies while improving outcomes and quality of life for patients with MPNs through collaborative research, education, and compassionate patient care.

Dr. John Mascarenhas is a Professor of Medicine at the Icahn School of Medicine at Mount Sinai (ISMMS) and a member of the Tisch Cancer Institute in New York City. Dr. Mascarenhas is the Director of Center of Excellence in Blood Cancers and Myeloid Disorders, Director of the Adult Leukemia Program, and Leader of Clinical Research within the Myeloproliferative Disorders Program at Mount Sinai. As a clinical investigator in malignant hematology with a focus in translational research involving MPNs, he is primarily responsible for the clinical trials portion of the Myeloproliferative Disorders Program at ISMMS. Dr. Mascarenhas is also the Principal Investigator (PI) of the clinical trials project within the National Cancer Institute sponsored Myeloproliferative Neoplasms Research Consortium (MPN-RC). He has served as PI or Study Chair of multiple investigator-initiated and industry-sponsored early and late phase clinical trials evaluating innovative approaches to the treatment of MPNs and secondary acute leukemia.